Maine is currently home to 217 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Bangor, Portland, Scarborough and Auburn. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Dissemination of the Donor Application: Utilizing Social Media to Identify Potential Live Organ Donors
NCT03803423
Recruiting
This study utilizes a web-based application to help patients on the organ transplant waitlist communicate patient's need for a living donor via social media and provide interested potential donors the opportunity to engage with the evaluation process.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/07/2023
Locations: Maine Medical Center, Portland, Maine
Conditions: End Stage Renal Disease, End Stage Liver Disease
Register for Updates
Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)
NCT05172024
Recruiting
This is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals who will enter the cohort with and without SARS-CoV-2 infection and at varying stages before and after infection. Individuals with and without SARS-CoV-2 infection and with or without Post-Acute Sequelae of COVID-19 (PASC) symptoms will be followed to identify risk factors and occurrence of PASC. This study will be conducted in the United States and subjects will be recruited through inpatien... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2023
Locations: MaineHealth, Portland, Maine
Conditions: SARS-CoV2 Infection
Register for Updates
Implementation of a Prehabilitation Program for Surgical Patients
NCT05377970
Recruiting
Frailty is a state of increased vulnerability to stressors with increased rates of poor outcomes. Surgery is one of these stressors, and previous research has therefore shown increased rates of morbidity and mortality in frail patients undergoing surgery. Prehabilitation programs can help mitigate the negative outcomes associated with frailty. The investigators hope to implement a newly developed prehabilitation pilot program in the Maine Medical Center Surgical Oncology Clinic to initially eval... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/22/2023
Locations: Maine Medical Center, Portland, Maine
Conditions: Prehabilitation, Oncology, Surgical Oncology
Register for Updates
Outcomes and Health Economics of Stroke Using Rhythmic Auditory Stimulation
NCT06051539
Recruiting
The purpose of this trial is to assess engagement, efficacy, durability, and impact on health care resource utilization of MR-001 in persons with chronic stroke who have a gait deficit after in-home/community use.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
10/20/2023
Locations: Curavit Clinical Research - DECENTRALIZED CLINICAL TRIAL, Portland, Maine
Conditions: Chronic Stroke
Register for Updates
Ceftriaxone to PRevent pneumOnia and inflammatTion aftEr Cardiac arresT (PROTECT)
NCT04999592
Recruiting
Randomized-controlled trial and microbiome assessment to understand the risk-to-benefit ratio of prophylactic antibiotics (Ceftriaxone) vs placebo in patients with pneumonia and inflammation after cardiac arrest outside the hospital.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/02/2023
Locations: Maine Medical Center, Portland, Maine
Conditions: Out-Of-Hospital Cardiac Arrest, Pneumonia
Register for Updates
Abatacept in Immune Checkpoint Inhibitor Myocarditis
NCT05335928
Recruiting
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/06/2023
Locations: Maine Health, Portland, Maine
Conditions: Myocarditis Acute, Cancer
Register for Updates
Study of Kidney Tumors in Younger Patients
NCT00898365
Recruiting
This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.
Gender:
All
Ages:
29 years and below
Trial Updated:
09/06/2023
Locations: Eastern Maine Medical Center, Bangor, Maine
Conditions: Adult Cystic Nephroma, Anaplastic Kidney Wilms Tumor, Angiolipoma, Cellular Congenital Mesoblastic Nephroma, Classic Congenital Mesoblastic Nephroma, Clear Cell Sarcoma of the Kidney, Congenital Mesoblastic Nephroma, Cystic Partially Differentiated Kidney Nephroblastoma, Diffuse Hyperplastic Perilobar Nephroblastomatosis, Extrarenal Rhabdoid Tumor, Kidney Medullary Carcinoma, Kidney Neoplasm, Kidney Oncocytoma, Kidney Wilms Tumor, Metanephric Adenofibroma, Metanephric Adenoma, Metanephric Stromal Tumor, Metanephric Tumor, Mixed Congenital Mesoblastic Nephroma, Ossifying Renal Tumor of Infancy, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions, Rhabdoid Tumor of the Kidney, Wilms Tumor
Register for Updates
Effects of Immulina TM Supplements With PASC Patients
NCT05524532
Recruiting
This is a multi-site study that will try to determine the effects of Immulina ™, a natural dietary supplement, on blood chemicals associated with inflammation that are often increased in patients with long COVID (also called PASC).
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
08/29/2023
Locations: MaineHealth, Portland, Maine
Conditions: Post Acute COVID-19 Syndrome
Register for Updates
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445
Recruiting
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/28/2023
Locations: Harold Alfond Center for Cancer Care, Augusta, Maine
Conditions: Previously Treated Non-Small Cell Lung Cancer
Register for Updates
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284
Recruiting
This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/18/2023
Locations: GSK Investigational Site, Scarborough, Maine
Conditions: Neoplasms
Register for Updates
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636
Recruiting
RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-VEGF therapies have significantly changed the landscape for treatment of wet AMD, b... Read More
Gender:
All
Ages:
Between 50 years and 89 years
Trial Updated:
08/17/2023
Locations: Maine Eye Center, Portland, Maine
Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
Register for Updates
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
NCT04205968
Recruiting
This phase II trial studies how well ramucirumab and paclitaxel or the FOLFIRI regimen (leucovorin calcium, fluorouracil, and irinotecan hydrochloride) work in treating patients with small bowel cancers that have spread extensively to other anatomic sites (advanced) or are no longer responding to treatment (refractory). Ramucirumab is a monoclonal antibody that attaches to and inhibits a molecule called VEGFR-2. This may restrain new blood vessel formation therefore reducing nutrient supply to t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: Lafayette Family Cancer Center-EMMC, Brewer, Maine
Conditions: Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8, Stage IIIB Small Intestinal Adenocarcinoma AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8
Register for Updates